STOKE THERAPEUT.DL-001
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-… Read more
Market Cap & Net Worth: STOKE THERAPEUT.DL-001 (0GT)
STOKE THERAPEUT.DL-001 (F:0GT) has a market capitalization of $1.70 Billion (€1.66 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #6535 globally and #696 in its home market, demonstrating a -1.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying STOKE THERAPEUT.DL-001's stock price €29.00 by its total outstanding shares 57117150 (57.12 Million).
STOKE THERAPEUT.DL-001 Market Cap History: 2019 to 2026
STOKE THERAPEUT.DL-001's market capitalization history from 2019 to 2026. Data shows growth from $1.38 Billion to $1.70 Billion (2.71% CAGR).
STOKE THERAPEUT.DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how STOKE THERAPEUT.DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0GT by Market Capitalization
Companies near STOKE THERAPEUT.DL-001 in the global market cap rankings as of March 19, 2026.
Key companies related to STOKE THERAPEUT.DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
STOKE THERAPEUT.DL-001 Historical Marketcap From 2019 to 2026
Between 2019 and today, STOKE THERAPEUT.DL-001's market cap moved from $1.38 Billion to $ 1.70 Billion, with a yearly change of 2.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.70 Billion | +7.41% |
| 2025 | €1.58 Billion | +157.14% |
| 2024 | €615.61 Million | +118.75% |
| 2023 | €281.42 Million | -42.51% |
| 2022 | €489.55 Million | -58.04% |
| 2021 | €1.17 Billion | -58.37% |
| 2020 | €2.80 Billion | +102.54% |
| 2019 | €1.38 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of STOKE THERAPEUT.DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.70 Billion USD |
| MoneyControl | $1.70 Billion USD |
| MarketWatch | $1.70 Billion USD |
| marketcap.company | $1.70 Billion USD |
| Reuters | $1.70 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.